In vitro antiviral activity of some novel isatin derivatives against HCV and SARS-CoV viruses | Zendy

Parasuraman Selvam | Zendy; N Murgesh | Zendy; Markandavel Chandramohan | Zendy; Erik De Clercq | Zendy; Els Keyaerts | Zendy; Leen Vijgen | Zendy; Piet Maes | Zendy; Johan Neyts | Zendy; MV Ranst | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

<i>In vitro</i> antiviral activity of some novel isatin derivatives against HCV and SARS-CoV viruses

Author(s) -

Parasuraman Selvam,

N Murgesh,

Markandavel Chandramohan,

Erik De Clercq,

Els Keyaerts,

Leen Vijgen,

Piet Maes,

Johan Neyts,

MV Ranst

Publication year - 2008

Publication title -

indian journal of pharmaceutical sciences

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.245

H-Index - 57

eISSN - 1998-3743

pISSN - 0250-474X

DOI - 10.4103/0250-474x.40339

Subject(s) - vero cell , virology , in vitro , isatin , hepatitis c virus , chemistry , virus , cytopathic effect , biology , biochemistry , organic chemistry

4-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)amino]-N(4,6-dimethyl-2-pyrimidiny)benzene sulphonamide and its derivatives were evaluated for antiviral activity against Pathogenic viruses such as Hepatitis C Virus and SARS-CoV in Vero and Huh 5-2 cells, respectively. The 5-fluoro derivative inhibited the HCV RNA synthesis at 6 mug/ml, without toxicity at a concentration up to 42 mug/ml in Huh 5-2 cells. Among the compounds tested SPIII-5F exhibits the 45% maximum protection against replication of SARS-CoV in Vero cells.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research